This position paper provides standardized guidance and specific cutoff points for the clinical application of fractional exhaled nitric oxide (FeNO) measurements in Korean populations with respiratory diseases.
Standardizes FeNO interpretation for asthma diagnosis in Korean patients; extends international guidelines with population-specific thresholds.
Nitric oxide (NO) is a biologic mediator of various physiologic functions. Recent evidence suggests the clinical utility of fractional exhaled NO (FeNO) as a biomarker for assessing asthma and other respiratory diseases. FeNO methodologies have been recently standardized by international research groups and subsequently validated in several Korean population studies. Normal ranges for FeNO have been reported for various ethnic groups, and the clinical utility has been widely evaluated in asthma and various respiratory diseases. Based on current evidence including most of Korean population data, this position paper aims to introduce the methodological considerations, and provide the guidance for the proper clinical application of FeNO measurements in Korean populations.
No takes yet. Share an insight, caveat, or question.
Song et al. (2014) conducted a review in Asthma and respiratory diseases. Fractional exhaled nitric oxide (FeNO) measurement was evaluated. Fractional exhaled nitric oxide (FeNO) levels greater than 50 ppb in adults and 35 ppb in children indicate a high likelihood of asthma or eosinophilic inflammation in Korean populations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: